CN109820865A - The application of xylo-oligosaccharide and the guar gum complex composition of partial hydrolysis in pre- preventing obesity and health care product - Google Patents
The application of xylo-oligosaccharide and the guar gum complex composition of partial hydrolysis in pre- preventing obesity and health care product Download PDFInfo
- Publication number
- CN109820865A CN109820865A CN201910281866.7A CN201910281866A CN109820865A CN 109820865 A CN109820865 A CN 109820865A CN 201910281866 A CN201910281866 A CN 201910281866A CN 109820865 A CN109820865 A CN 109820865A
- Authority
- CN
- China
- Prior art keywords
- phgg
- xos
- lipid food
- high lipid
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention provides the application of xylo-oligosaccharide and the guar gum complex composition of partial hydrolysis in preparation prevention antiobesity agents and health care product, belong to the function and application field of natural plant active component.The present invention simulates the generation of obesity by using the mode that high lipid food is raised, to probe into XOS and PHGG compounding to the preventive effect of the obesity as caused by high fat diet.Excess weight growth, the increase of liver kidney weight, body fat accumulation and liver lipid level caused by XOS and PHGG compounding can inhibit by high fat diet increase, and illustrate that XOS and PHGG compounding can prevent the obesity induced by high fat diet.Therefore, the generation of obesity can effectively be prevented by XOS and PHGG compounding being succeeded in developing energy sex-health products.
Description
Technical field
The invention belongs to the function of natural plant active component and application fields, and in particular to xylo-oligosaccharide and partial hydrolysis
Guar gum complex composition preparation prevention antiobesity agents and health care product in application.
Background technique
Xylo-oligosaccharide (XOS) and the guar gum (PHGG) of partial hydrolysis are all a kind of natural water-soluble dietary fibers,
Although the two cannot all be absorbed by mammalian digestive, it is easy in enteron aisle to increase beneficial bacterium and harmful bacteria by bacterial fermentation
Ratio, thus play the role of adjust intestinal flora.As middle a member of dietary fiber, XOS and PHGG have most of meals
The characteristic that food fiber has, such as strengthen immunity, improvement function of intestinal canal and hypoglycemic healthcare function.
Obesity is a kind of chronic metabolic disease as caused by many factors, including heredity, drug, metabolic rate, endocrine
Function, nutrition and other environmental factors etc. increase the percentage for causing body fat percentage of liveweight with the volume of body fat cell and cell number
Increase and with the characteristics of certain parts excessively deposit fat than abnormal.Constitutional index (BMI) is common in the world at present measures
The fat or thin degree of human body and whether Jian Kang a standard, be with weight kilogram number divided by several squares of numbers obtained of height rice,
BMI index is greater than 25 and is defined as overweight by the World Health Organization, and BMI index, which is greater than, 30 is defined as obesity.Obesity has become one
A global public health problem.It is shown according to " world health counts (2015) " of World Health Organization's publication in 2015,
In the whole world in 2014 18 years old and the above adult, it is more than 1,900,000,000 adult overweight that overweight population, which accounts for 39%, and population of being obese accounts for 13%, super
It is adult fat to cross 600,000,000.Famous medical journals " THE LANCET " research report in 2014 points out that Chinese population of being obese will in 2014
Nearly 90,000,000, population of being obese number ranking the first in the world.Obesity itself is not only a kind of chronic disease, but also itself and a variety of chronic diseases
Closely related, such as diabetes, fatty liver and cardiovascular disease occurs.Therefore, pre- preventing obesity is for reducing related disease
Morbidity and mortality are vital.
Current diet products more or less have bigger side effect to human body, are such as supervised and manage by U.S.'s food and medicine
The slimming drugs orlistat of reason office (FDA) certification, common side effect are gastrointestinal side effect, and accidental anxiety, is exhaled at allergy
The adverse reactions such as road infection are inhaled, in recent years, many studies have shown that it is fat closely related with intestinal flora, and mended by some diets
Agent adjustment intestinal tract flora metabolite is filled, to treatment or fat and its related disease may be improved with positive effect.
The present invention is by a large amount of application foundation experiments have shown that XOS and PHGG compounding can improve as caused by high fat diet
Obesity.Therefore, XOS and PHGG compounding can be used for pre- preventing obesity and its related disease.
Summary of the invention
Obesity is the disease by various heredity or such environmental effects, and still there are many not in prevention and treatment at present
Foot, and most of obesity treatment drugs are unfavorable for the health of human body.The purpose of the present invention is to provide xylo-oligosaccharides and portion
Divide application of the guar gum complex composition of hydrolysis in preparation prevention antiobesity agents and health care product.
To achieve the above object, the present invention adopts the following technical scheme:
Present invention content to be protected is that the guar gum complex composition of xylo-oligosaccharide and partial hydrolysis is preparing pre- preventing obesity
Application in drug and health care product.
In the complex composition, the mass ratio of xylo-oligosaccharide and guar gum is 2:1.
Weight, Lees index, liver kidney weight and the body fat accumulation of obesity mice increase obvious, triglycerides, total gallbladder
Sterol, low-density lipoprotein increase to be reduced with high-density lipoprotein.We research has shown that, XOS and PHGG compounding can inhibit
The excess weight as caused by high fat diet increases, liver kidney weight increases, body fat accumulation and liver lipid level increase, to reach
To the effect of pre- preventing obesity.
Remarkable advantage of the invention is: correlative study of the present invention has found that XOS and PHGG compounding can pass through control for the first time
Mouse weight processed increases and improves the basic biochemical indicator of liver, has the function that pre- preventing obesity, this prevents Future Development, preparation
Fat drug provides important experiment basis and scientific basis.
Detailed description of the invention
The changes of weight tendency chart of mouse during Fig. 1 is experiment.After eight weeks, high lipid food group mouse weight is significantly higher than just
Normal feed group, high lipid food+XOS+PHGG group weight are substantially less than high lipid food group, illustrate that XOS and PHGG compounding can prevent
By the weight gain caused by high lipid food.# p< 0.05, chow diet vs high lipid food；*p< 0.05, high lipid food vs is high in fat
Feed+XOS+PHGG；Based on t-test.
Fig. 2 is the result figure of mouse liver weight after testing.It can be seen from the figure that high lipid food group mouse liver
Though weight slightly above chow diet group, does not have statistical significance, high lipid food+XOS+PHGG group liver weight is substantially less than
High lipid food group.*p< 0.05, high lipid food vs high lipid food+XOS+PHGG；Based on t-test.
Fig. 3 is the result figure of mouse kidney weight after testing.It can be seen from the figure that high lipid food group mouse liver
Weight is significantly higher than chow diet group, and high lipid food+XOS+PHGG group liver weight is substantially less than high lipid food group.# p< 0.05,
Chow diet vs high lipid food；*p< 0.05, high lipid food vs high lipid food+XOS+PHGG；Based on t-test.
Fig. 4 be experiment after mouse liver be sliced H&E colored graph (200 ×), A-C respectively indicate chow diet group,
High lipid food group and high lipid food+XOS+PHGG group.It can be seen from the figure that comparing chow diet group, high lipid food group mouse
Occur a small number of white vacuoles in liver section, and compare high lipid food group, high lipid food+XOS+PHGG organizes mouse liver and is sliced base
Exist in sheet without white vacuole.
Fig. 5 is the result figure of mouse epididymis fat weight after testing.It can be seen from the figure that high lipid food group mouse
Epididymal adipose tissues weight is significantly higher than chow diet group, and high lipid food+XOS+PHGG group epididymal adipose tissues weight is substantially less than feeding high in fat
Material group.# p< 0.05, chow diet vs high lipid food；*p< 0.05, high lipid food vs high lipid food+XOS+PHGG；Based on t-
test。
Fig. 6 is the result figure of mouse liver content of triglyceride after testing.It can be seen from the figure that high lipid food group
Mouse liver content of triglyceride is significantly higher than chow diet group, and it is aobvious that high lipid food+XOS+PHGG organizes liver tg content
It writes and is lower than high lipid food group.# p< 0.05, chow diet vs high lipid food；*p< 0.05, high lipid food vs high lipid food+XOS+
PHGG；Based on t-test.
Fig. 7 is the result figure of mouse liver total cholesterol level after testing.It can be seen from the figure that high lipid food group
Mouse liver total cholesterol level is significantly higher than chow diet group, and it is aobvious that high lipid food+XOS+PHGG organizes total cholesterol of liver content
It writes and is lower than high lipid food group.# p< 0.05, chow diet vs high lipid food；*p< 0.05, high lipid food vs high lipid food+XOS+
PHGG；Based on t-test.
Fig. 8 is the result figure of mouse liver low-density lipoprotein content after testing.It can be seen from the figure that feeding high in fat
Material group mouse liver low-density lipoprotein content is significantly higher than chow diet group, and high lipid food+XOS+PHGG organizes liver low-density
Lipoprotein content is substantially less than high lipid food group.# p< 0.05, chow diet vs high lipid food；*p< 0.05, high lipid food vs high
Rouge feed+XOS+PHGG；Based on t-test.
Fig. 9 is the result figure of mouse liver hdl concentration after testing.It can be seen from the figure that feeding high in fat
Material group mouse liver hdl concentration is significantly higher than chow diet group, and high lipid food+XOS+PHGG organizes liver high density
Lipoprotein content is substantially less than high lipid food group.# p< 0.05, chow diet vs high lipid food；*p< 0.05, high lipid food vs high
Rouge feed+XOS+PHGG；Based on t-test.
Specific embodiment
In order to make content of the present invention easily facilitate understanding, With reference to embodiment to of the present invention
Technical solution is described further, but the present invention is not limited only to this.
The acquisition of XOS, is provided by Shandong Longli Biology Science and Technology Co., Ltd.
The preparation of PHGG, guar gum is by inscribe-β-D mannase, in pH=6, under the conditions of temperature is 50 DEG C, incubates
It educates 2 ~ 3 hours, degrades.Then, using one 732 cation exchange resin of D315 macroreticular resin, one 717 anion exchange tree
The resin combination of rouge carries out the purification processes of desalination, decoloration, deodorization to degradation solution.Purification liquid is freeze-dried to obtain sample.It utilizes
The molecular weight of liquid chromatographic detection sample (average molecular weight is in 20kDa).Sample is made and is used for subsequent experimental.
Experimental subjects is 18 male C57BL/6 mouse similar in weight, and 6 are only used as negative control group, feeds normal raise
Material, 6 are only used as positive controls, feed high lipid food, and residue 6 is only used as experimental group, stomach-filling 300 while feeding high lipid food
The XOS of the PHGG of mg/kg and 600 mg/kg, experiment carry out 8 weeks.After experiment, mouse is dissected, collects serum, internal organs, attached
Testis fat.See Table 1 for details -2 for chow diet and high lipid food composition information table.
1 chow diet composition information table of table
Note: chow diet of the present invention is the most common chow diet of zoopery.
2 high lipid food of table (D12492) composition information table
Note: high lipid food (D12492) of the present invention is to establish the most common high lipid food of fat animal model.
Mouse liver slice uses the film-making of H&E colouring method.
The detection of liver tg, total cholesterol, low-density lipoprotein bletilla high-density lipoprotein, accurately weighs tissue weight
Amount, by weight (g): volume (ml)=1:9 ratio is added the homogenate medium of 9 times of volumes, mechanical homogenisation under the conditions of ice-water bath,
2500 rpm/min are centrifuged 10 minutes, take supernatant to be measured, and operating procedure is carried out by kit specification.
Statistical procedures
For statistical analysis using Excel, each group of data indicates that experimental data is equal with average ± standard error (Mean ± SEM)
It is examined using t-test, statistical significance difference is set in 0.05 (i.e. P < 0.05).It is soft using GraphPad Software 5.0
The drafting of part completion chart.
As a result as shown in Fig. 1-9 and table 3.
Table 3
Table 1 is the result figure of mouse Lees index after testing.As can be seen from the table, high lipid food group mouse Lees index
It is significantly higher than chow diet group, high lipid food+XOS+PHGG group Lees index is substantially less than high lipid food group, further illustrates
XOS and PHGG compounds the weight gain caused by can preventing by high lipid food.# p< 0.05, chow diet vs high lipid food；*p
< 0.05, high lipid food vs high lipid food+XOS+PHGG；Based on t-test.
The above results show that XOS and PHGG compounding can prevent the obesity induced by high lipid food.In this experiment,
Mouse is fed using high lipid food, the simulation mankind take in the obesity that high fat diet is induced for a long time, and inquiring into XOS and PHGG compounding is
The no obesity that can prevent to be induced by high fat diet.Our experiments show that XOS and PHGG compounding can be by inhibiting by high in fat
Excess weight caused by diet increases, liver kidney weight increases, body fat accumulation and liver lipid level increase to reach prevention fertilizer
Fat generation.Therefore, XOS and PHGG compounding exploitation can be used for the preparation of slimming medicine and health care product.
The foregoing is merely presently preferred embodiments of the present invention, all equivalent changes done according to scope of the present invention patent with
Modification, is all covered by the present invention.
Claims (2)
1. the application of xylo-oligosaccharide and the guar gum complex composition of partial hydrolysis in pre- preventing obesity and health care product.
2. application according to claim 1, it is characterised in that: in the complex composition, xylo-oligosaccharide and partial hydrolysis
Guar gum mass ratio be 2:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910281866.7A CN109820865A (en) | 2019-04-09 | 2019-04-09 | The application of xylo-oligosaccharide and the guar gum complex composition of partial hydrolysis in pre- preventing obesity and health care product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910281866.7A CN109820865A (en) | 2019-04-09 | 2019-04-09 | The application of xylo-oligosaccharide and the guar gum complex composition of partial hydrolysis in pre- preventing obesity and health care product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109820865A true CN109820865A (en) | 2019-05-31 |
Family
ID=66874331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910281866.7A Pending CN109820865A (en) | 2019-04-09 | 2019-04-09 | The application of xylo-oligosaccharide and the guar gum complex composition of partial hydrolysis in pre- preventing obesity and health care product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109820865A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049162A (en) * | 2007-05-21 | 2007-10-10 | 北京东方兴企食品工业技术有限公司 | Nutrition protein powder containing beneficial bacteria |
| CN102595934A (en) * | 2009-11-12 | 2012-07-18 | 雀巢产品技术援助有限公司 | Nutritional composition for promoting gut microbiota balance and health |
| WO2016149687A1 (en) * | 2015-03-18 | 2016-09-22 | Whole Biome, Inc. | Methods and compositions relating to microbial treatment and diagnosis of skin disorders |
| CN106072150A (en) * | 2016-07-21 | 2016-11-09 | 深圳市四季优美贸易有限公司 | A kind of green plum with cosmetic slimming function and preparation method thereof |
-
2019
- 2019-04-09 CN CN201910281866.7A patent/CN109820865A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049162A (en) * | 2007-05-21 | 2007-10-10 | 北京东方兴企食品工业技术有限公司 | Nutrition protein powder containing beneficial bacteria |
| CN102595934A (en) * | 2009-11-12 | 2012-07-18 | 雀巢产品技术援助有限公司 | Nutritional composition for promoting gut microbiota balance and health |
| WO2016149687A1 (en) * | 2015-03-18 | 2016-09-22 | Whole Biome, Inc. | Methods and compositions relating to microbial treatment and diagnosis of skin disorders |
| CN106072150A (en) * | 2016-07-21 | 2016-11-09 | 深圳市四季优美贸易有限公司 | A kind of green plum with cosmetic slimming function and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| W. J. PASMAN ET AL.: "Effect of One Week of Fibre Supplementation on Hunger and Satiety Ratings and Energy Intake", 《APPETITE》 * |
| XIAODAN FU ET AL: "Study on the ability of partially hydrolyzed guar gum to modulate the gut microbiota and relieve constipation", 《J FOOD BIOCHEM》 * |
| 尹利端等: "低聚木糖在保健食品中的应用", 《技术装备》 * |
| 翁祖铨等: "基于肠道菌群探讨低聚木糖及复配物对高脂饮食诱导的肥胖小鼠的影响", 《中国营养学会第十四届全国营养科学大会暨第十一届亚太临床营养大会》 * |
| 谢全喜等: "低聚木糖的研究进展", 《畜牧与饲料科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Genta et al. | Subchronic 4-month oral toxicity study of dried Smallanthus sonchifolius (yacon) roots as a diet supplement in rats | |
| Guo et al. | Seabuckthorn (Hippophaë rhamnoides) freeze-dried powder protects against high-fat diet-induced obesity, lipid metabolism disorders by modulating the gut microbiota of mice | |
| CN102160614B (en) | Compound preparation for improving immunity of human bodies and enhancing bone density and application thereof | |
| CN111254090B (en) | Lactobacillus reuteri with weight losing function and application thereof | |
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| CN113398144B (en) | Application of nucleotide mixture in preparation of preparation for preventing or relieving sarcopenia of old people | |
| He et al. | Effects of dietary yeast β-glucan supplementation on meat quality, antioxidant capacity and gut microbiota of finishing pigs | |
| CN106722934B (en) | Anti-aging health food containing earthworm and clam worm peptide-containing extract | |
| CN115887485A (en) | Application of pachyman in regulating intestinal microbial structure and metabolite of obese organism | |
| CN109892555A (en) | A kind of diet food and preparation method thereof for hindering Fatty synthesis to accelerate oil extraction fat reducing | |
| CN108403970B (en) | Prebiotic composition and preparation method and application thereof | |
| CN109820865A (en) | The application of xylo-oligosaccharide and the guar gum complex composition of partial hydrolysis in pre- preventing obesity and health care product | |
| CN102106895A (en) | Composition with function of regulating blood fat | |
| CN104872286A (en) | Comprehensive-nutrition formula donkey milk powder with function of protecting heart and brain for middle-aged and old people and preparation method thereof | |
| Kang et al. | Anti-obesity effects of SPY fermented with lactobacillus rhamnosus BST-L. 601 via suppression of adipogenesis and lipogenesis in high-fat diet-induced obese mice | |
| CN108619367A (en) | A kind of Chinese medicine composition is preparing the application in preventing the drug of Acute cardiotoxicity caused by adriamycin | |
| Liu et al. | Effects of burdock inulin-type fructans exposure on the physiological function of healthy mice and their filial generation | |
| CN104256576B (en) | Functional food capable of regulating blood pressure | |
| CN101732323B (en) | Application of low-dose ursolic acid as medicament for treating diabetic early nephropathy | |
| CN101897399B (en) | Pineapple polysaccharide crude and preparation method thereof | |
| CN101879190A (en) | Composition containing curcumin and application of curcumin in preparing composition for adjusting blood sugar | |
| Zhang et al. | Effects of Chinese herbal formula Heat-stress-releasing on antioxidant function in dairy cows | |
| Zou et al. | Milk Fat Globule Membrane Relieves Fatigue via Regulation of Oxidative Stress and Gut Microbiota in BALB/c Mice | |
| CN110400640A (en) | A kind of research method of low carbohydrate diet to non-alcoholic fatty liver disease | |
| Koza et al. | Asteraceae seeds as alternative ingredients in a fibre-rich diet: Protein quality and metabolic effects in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190531 |
|
| RJ01 | Rejection of invention patent application after publication |